Accord Healthcare launches Lurasidone HCL tablets
22 February 2023 -

Accord Healthcare, Inc., a UK-based generic pharmaceutical company, announced on Tuesday that it has added Lurasidone HCL tablets to its range of generic drugs.

Accord's product is AB-rated to Sunovion Pharma's Latuda and is being offered in 20mg, 40mg, 60mg, 80mg, and 120mg doses in 30-count bottles.

The company said that Lurasidone is an oral, atypical antipsychotic, which is a first-line treatment option for the management of schizophrenia in adults and adolescents. Atypical antipsychotics have lower potential for extrapyramidal side effects. Laurasidone is claimed to rebalance dopamine and serotonin to improve thinking, mood, and behaviour.

Divya Verma, Accord Healthcare vice president, Marketing & Portfolio, said, 'By offering lurasidone, we hope to reduce the burden of costs of long-term treatment for individuals who can benefit from this medication. A generic option in mental health treatment provides more accessible healthcare to those who are in need.'